42404-24-0

Basic information

• Product Name: alpha-ethyl-N-hydroxybenzeneacetamidine
• Synonyms: alpha-ethyl-N-hydroxybenzeneacetamidine;2-Phenyl-N1-hydroxybutanimidamide
• CAS NO: 42404-24-0
• Molecular Formula: C₁₀H₁₄N₂O
• Molecular Weight: 178.23096
• EINECS: 255-805-1
• Mol File: 42404-24-0.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 339.619 °C at 760 mmHg
• Flash Point: 159.196 °C
• Appearance: /
• Density: 1.094 g/cm³
• CAS DataBase Reference: alpha-ethyl-N-hydroxybenzeneacetamidine(CAS DataBase Reference)
• NIST Chemistry Reference: alpha-ethyl-N-hydroxybenzeneacetamidine(42404-24-0)
• EPA Substance Registry System: alpha-ethyl-N-hydroxybenzeneacetamidine(42404-24-0)

Safety Data

• Hazardous Substances Data: 42404-24-0(Hazardous Substances Data)

Usage

Properties

1. Nonsteroidal anti-inflammatory drug (NSAID)
2. Used in the treatment of painful inflammatory conditions such as arthritis, bursitis, tendonitis, and sports injuries
3. Inhibits the production of inflammatory prostaglandins
4. Available in topical forms such as gels, creams, and ointments
5. Provides localized relief through absorption in the skin
6. Effective and well-tolerated for managing musculoskeletal pain and inflammation
7. May have potential side effects and contraindications

Specific content

1. Chemical name: Alpha-ethyl-N-hydroxybenzeneacetamidine
2. Common name: Etofenamate
3. Mechanism of action: Inhibiting the production of inflammatory prostaglandins
4. Route of administration: Topical
5. Forms available: Gels, creams, ointments
6. Indications: Arthritis, bursitis, tendonitis, sports injuries
7. Risks: Potential side effects and contraindications
8. Administration guidance: Use under the guidance of a healthcare professional

Upstream product

• 769-68-6 2-phenylbutanenitrile 

Relevant articles and documents

OXADIAZOLE COMPOUNDS

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.